rapamycin
deriv
specif
inhibitor
mammalian
target
rapamycin
mtor
kinas
result
wellestablish
immunosuppress
antitumorigen
agent
addit
class
drug
promot
gene
deliveri
facilit
lentivir
vector
entri
cell
reveal
potenti
improv
gene
therapi
effort
howev
precis
mechan
unknown
report
mtor
inhibitor
treatment
result
downregul
ifninduc
transmembran
ifitm
protein
ifitm
protein
especi
potent
inhibitor
viruscel
fusion
broadli
activ
rang
pathogen
virus
found
effect
rapamycin
treatment
lentivir
transduct
diminish
upon
ifitm
silenc
knockout
primari
transform
cell
extent
transduct
enhanc
depend
basal
express
ifitm
protein
major
contribut
effect
rapamycin
treatment
manifest
level
protein
mrna
select
mani
endosomeassoci
transmembran
protein
unaffect
rapamycinmedi
degrad
requir
endosom
traffick
ubiquitin
endosom
sort
complex
requir
transport
escrt
machineri
lysosom
acidif
sinc
ifitm
protein
exhibit
broad
antivir
activ
show
mtor
inhibit
also
promot
infect
anoth
ifitmsensit
viru
influenza
viru
infect
sendai
viru
ifitmresist
result
identifi
molecular
basi
mtor
inhibitor
enhanc
viru
entri
cell
reveal
previous
unrecogn
immunosuppress
featur
clinic
import
drug
addit
studi
uncov
function
converg
mtor
pathway
ifitm
protein
endolysosom
membran
fusion
endosom
ifitm
interferon
viru
rapamycin
deriv
specif
inhibitor
mammalian
target
rapamycin
mtor
kinas
result
wellestablish
immunosuppress
antitumorigen
agent
addit
class
drug
promot
gene
deliveri
facilit
lentivir
vector
entri
cell
reveal
potenti
improv
gene
therapi
effort
howev
precis
mechan
unknown
report
mtor
inhibitor
treatment
result
downregul
ifninduc
transmembran
ifitm
protein
ifitm
protein
especi
potent
inhibitor
viruscel
fusion
broadli
activ
rang
pathogen
virus
found
effect
rapamycin
treatment
lentivir
transduct
diminish
upon
ifitm
silenc
knockout
primari
transform
cell
extent
transduct
enhanc
depend
basal
express
ifitm
protein
major
contribut
effect
rapamycin
treatment
manifest
level
protein
mrna
select
mani
endosomeassoci
transmembran
protein
unaffect
rapamycinmedi
degrad
requir
endosom
traffick
ubiquitin
endosom
sort
complex
requir
transport
escrt
machineri
lysosom
acidif
sinc
ifitm
protein
exhibit
broad
antivir
activ
show
mtor
inhibit
also
promot
infect
anoth
ifitmsensit
viru
influenza
viru
infect
sendai
viru
ifitmresist
result
identifi
molecular
basi
mtor
inhibitor
enhanc
viru
entri
cell
reveal
previous
unrecogn
immunosuppress
featur
clinic
import
drug
addit
studi
uncov
function
converg
mtor
pathway
ifitm
protein
endolysosom
membran
fusion
endosom
ifitm
interferon
viru
e
ndosom
vesicular
membranebound
organel
direct
intern
sort
fluid
macromolecul
plasma
membran
protein
via
process
endocytosi
invagin
plasma
membran
care
regul
fission
event
give
rise
earli
endocyt
vesicl
ferri
cargo
recycl
circuit
content
return
cell
surfac
pathway
termin
highli
acidifi
lysosom
protein
transport
lysosom
occur
follow
lysosom
fusion
late
endosom
special
structur
known
autophagosom
former
late
endosom
deliv
enzym
need
lysosom
function
well
endocytos
materi
destin
proteolyt
degrad
fusion
late
endosom
lysosom
give
rise
hybrid
organel
known
endolysosom
name
also
use
gener
describ
late
endosomelysosom
compart
sinc
method
distinguish
inadequ
late
endosom
also
known
multivesicular
bodi
mvb
due
presenc
intralumin
vesicl
ilv
endosom
sort
complex
requir
transport
escrt
machineri
requir
sort
ubiquitin
protein
cargo
ilv
subsequ
degrad
lysosom
hydrolas
late
endosomesmvb
fuse
lysosom
overal
intric
traffick
membran
protein
regul
specif
cellular
activ
nutrient
uptak
signal
transduct
collect
allow
cell
rapidli
respond
surround
provid
mean
larg
molecul
access
otherwis
imperm
cell
endocyt
network
also
exploit
portal
entri
pathogen
mani
pathogen
envelop
virus
infect
human
includ
influenza
viru
iav
dengu
viru
ebola
viru
adher
life
cycl
reli
endosom
movement
matur
progress
acidif
occur
transit
earli
endosom
late
endosom
trigger
fusion
viral
endosom
membran
allow
cytoplasm
access
initi
viral
replic
endosom
thu
situat
crucial
cellular
threshold
result
equip
element
cellintrins
antivir
immun
respons
ifninduc
transmembran
ifitm
protein
antivir
factor
inhibit
infect
divers
assort
virus
level
viruscel
fusion
found
endolysosom
membran
relat
local
rather
plasma
membran
exhibit
differenti
antivir
specif
howev
studi
ifitm
protein
function
perform
use
ectop
express
assay
less
known
endogen
role
play
differ
cell
type
express
upregul
interferon
cytokin
certain
tissu
type
ifitm
protein
highli
express
basal
condit
exampl
ifitm
member
readili
detect
skin
cell
includ
dermal
foreskin
fibroblast
mucos
epithelium
epitheli
cell
like
astrocyt
hela
signific
gene
deliveri
viruslik
particl
hold
enorm
therapeut
potenti
correct
inherit
genet
disord
prevent
infecti
diseas
howev
cell
express
antivir
factor
prevent
viru
infect
consequ
limit
success
gene
therapi
reveal
mechan
drug
rapamycin
improv
lentivirusmedi
gene
deliveri
rapamycin
treatment
led
degrad
broad
potent
antivir
protein
inhibit
viru
entri
cell
select
clear
endosom
site
viral
cellular
membran
fuse
sort
dispos
lysosom
reveal
immunosuppress
function
clinic
benefit
caution
rapamycin
use
human
may
facilit
infect
pathogen
virus
like
influenza
viru
cell
addit
found
hematopoiet
stem
cell
progenitor
includ
myeloid
lymphoid
cell
type
macrophag
dendrit
cell
cell
express
level
affect
differenti
activ
statu
case
function
util
ifitm
protein
may
limit
antivir
protect
sinc
also
believ
perform
cellular
function
beyond
restrict
viru
entri
much
understood
antivir
activ
ifitm
protein
result
retrovir
pseudotyp
experi
pseudotyp
process
retrovirus
hiv
murin
leukemia
viru
outfit
heterolog
envelop
glycoprotein
iav
hemagglutinin
ha
vesicular
stomat
viru
vsv
glycoprotein
vsvg
sinc
viral
glycoprotein
bind
distinct
cell
surfac
receptor
perform
fusion
reaction
distinct
cellular
membran
pseudotyp
allow
custom
deliveri
viru
particl
select
cell
type
select
intracellular
compart
endosom
practic
extend
clinic
set
vsvg
current
use
guid
deliveri
retroviru
human
cell
gene
therapi
effort
due
abil
vsvg
bind
ubiquit
ldl
receptor
cell
attach
overexpress
inhibit
viru
entri
mediat
iav
ha
vsvg
former
consider
sensit
inhibit
latter
furthermor
ko
mice
exhibit
enhanc
morbid
mortal
challeng
subleth
dose
iav
polymorph
human
associ
sever
diseas
outcom
follow
iav
infect
howev
unclear
whether
ifitm
protein
restrict
vsvgmediat
viru
entri
situat
clinic
consequ
human
mammalian
target
rapamycin
mtor
serin
threonin
kinas
function
central
regul
cell
growth
metabol
deregul
mtor
pathway
contribut
mani
human
diseas
includ
cancer
obes
diabet
agerel
patholog
name
impli
discoveri
function
character
mtor
fundament
link
natur
compound
inhibit
rapamycin
bind
protein
duo
act
alloster
inhibitor
mtor
compon
two
complex
known
mtor
integr
signal
nutrient
growth
factor
energi
oxygen
promot
protein
lipid
synthesi
cell
prolifer
surviv
macroautophagi
suppress
rapamycin
deriv
inhibit
anabol
cellular
process
evalu
approv
medicin
use
anticanc
agent
treat
graftversushost
diseas
transplant
patient
gener
believ
sensit
rapamycin
latter
also
inhibit
drug
use
extend
period
high
concentr
local
endomembran
regul
metabol
activ
unknown
whether
mtorassoci
signal
influenc
event
subcellular
compart
viru
entri
recent
describ
rapamycin
treatment
enhanc
gene
deliveri
lentivir
vector
human
murin
hematopoiet
stem
progenitor
cell
hspc
effect
observ
use
replicationincompet
lentiviru
lentivector
pseudotyp
vsvg
current
favor
tool
genom
modif
ex
vivo
due
abil
maxim
infect
broaden
cellular
tropism
without
compromis
longterm
engraft
initi
report
found
rapamycin
promot
lentivector
fusion
cellular
membran
detail
mechan
remain
unknown
nonetheless
use
rapamycin
deriv
alreadi
includ
gene
therapi
protocol
correct
prevent
multipl
human
diseas
includ
hivaid
discoveri
reveal
previous
uncharacter
connect
mtor
endocyt
traffick
viruscel
fusion
articl
report
mtor
inhibitor
includ
rapamycin
downregul
endogen
lysosom
degrad
pathway
hematopoiet
nonhematopoiet
cell
furthermor
rapamycin
enhanc
lentivector
transduct
also
iav
infect
primari
transform
cell
line
manner
studi
improv
gene
modif
effici
facilit
effort
correct
varieti
human
diseas
furthermor
novel
strategi
directli
target
cellular
ifitm
protein
yield
gene
therapi
maxim
gene
modif
cell
engraft
cell
surviv
bypass
unintend
consequ
mtor
inhibitor
use
furthermor
result
reveal
mtor
inhibitor
reliev
broadli
act
intrins
antivir
barrier
promot
viral
infect
ex
vivo
rais
possibl
use
clinic
set
may
undermin
antivir
immun
vivo
thu
rapamycin
deriv
mtor
inhibitor
may
repres
doubleedg
sword
arena
public
health
endogen
downregul
rapamycin
via
lysosom
degrad
pathway
inhibitor
viruscel
fusion
endosom
assess
role
play
ifitm
protein
rapamycinmedi
enhanc
lentivector
infect
previous
report
hela
cell
primari
fibroblast
express
high
level
render
refractori
infect
zika
viru
hela
expos
micromolar
quantiti
rapamycin
h
observ
dosedepend
decreas
protein
determin
flow
cytometri
western
blot
analysi
fig
ac
effect
select
anoth
transmembran
protein
transferrin
receptor
unaffect
rapamycin
treatment
fig
time
cours
experi
reveal
downregul
progress
maxim
decreas
observ
h
posttreat
transient
protein
level
partial
recov
time
fig
e
also
examin
mtor
inhibit
affect
endogen
induc
type
ifn
cell
follow
h
ifn
stimul
rapamycin
addit
led
decreas
level
induc
protein
dosedepend
manner
elev
amount
rapamycin
result
stabl
nontransi
loss
induc
si
appendix
fig
use
quantit
rtpcr
show
mrna
level
unaffect
rapamycin
fig
indic
downregul
manifest
protein
level
second
mtor
inhibitor
torin
also
shown
enhanc
lentivector
transduct
hspc
downregul
endogen
micromolar
rang
well
si
appendix
fig
agreement
model
posttransl
regul
found
vacuolar
atpas
inhibitor
bafilomycin
partial
prevent
rapamycinmedi
downregul
fig
g
h
indic
endolysosom
acidif
contribut
protein
degrad
mtor
inhibit
meanwhil
endosom
traffick
inhibitor
function
independ
acidif
also
partial
rescu
protein
level
proteasom
inhibitor
effect
fig
g
h
explor
mechan
downregul
molecular
detail
studi
fate
exogen
stabli
transfect
cell
rapamycin
treatment
result
decreas
wt
protein
mutant
variant
prolinebas
ppxi
site
recogn
ubiquitin
ligas
disrupt
partial
resist
downregul
si
appendix
fig
similarli
previous
describ
ubiquitindefici
variant
lysin
chang
arginin
display
loss
sensit
rapamycinmedi
degrad
furthermor
mutant
lack
recognit
site
critic
tyrosin
need
endocytosi
complet
resist
effect
rapamycin
fig
si
appendix
fig
experiment
system
exogen
protein
sensit
rapamycin
resist
si
appendix
fig
differenti
effect
rapamycin
close
relat
ifitm
protein
explain
fact
recognit
endocytosi
motif
present
amino
termini
absent
togeth
data
suggest
mtor
inhibitor
redirect
protein
toward
proteolyt
pathway
requir
endocytosi
ubiquitin
endolysosom
acidif
confirm
mtor
inhibitor
treatment
decreas
protein
halflif
treat
hela
cell
rapamycin
presenc
cycloheximid
chx
h
rapamycin
acceler
protein
turnov
condit
bafilomycin
inhibit
loss
fig
endocyt
traffick
elucid
mechan
protein
target
endolysosom
degrad
studi
effect
rapamycin
treatment
fix
cell
use
confoc
immunofluoresc
microscopi
primari
human
foreskin
fibroblast
hff
hela
cell
rapamycin
treatment
reduc
level
bafilomycin
manner
fig
mocktreat
cell
endogen
local
earli
endosom
lesser
extent
endolysosom
determin
costain
si
appendix
fig
howev
rapamycin
treatment
result
abrupt
clearanc
site
without
affect
level
fig
si
appendix
fig
b
c
addit
rapamycin
bafilomycin
led
retent
reticul
saclik
structur
surround
nucleu
fig
endolysosom
enrich
condit
confirm
use
rfptag
tzmbl
cell
line
also
express
high
level
endogen
fig
si
appendix
fig
enabl
track
live
cell
includ
yfptag
analysi
rapamycin
treatment
led
redistribut
compart
posit
lysotrack
reagent
suggest
posttransl
degrad
program
termin
acid
endolysosom
fig
resolv
mechan
deliv
proteolyt
lumen
endolysosom
mtor
inhibit
consid
involv
two
cellular
pathway
macroautophagi
mvb
format
sinc
rapamycin
commonli
use
induc
macroautophagi
cultur
cell
test
whether
rapamycinmedi
degrad
requir
autophagosom
format
concomit
treatment
cell
rapamycin
bafilomycin
result
accumul
endolysosom
structur
gener
decor
autophagosom
marker
si
appendix
fig
directli
assess
contribut
autophagi
evalu
effect
serum
amino
acid
depriv
tzmbl
hff
cell
rapamycin
treatment
result
convers
phosphatidylethanolamineconjug
recruit
autophagosom
membran
si
appendix
fig
b
convers
subsequ
loss
reflect
autophag
flux
degrad
inhibit
bafilomycin
rapamycin
promot
turnov
starvat
cell
durat
rapamycin
treatment
led
greater
loss
affect
level
lesser
extent
si
appendix
fig
suggest
two
mode
mtor
inhibit
differ
regard
extent
rapid
degrad
furthermor
indic
degrad
uncoupl
mtor
inhibit
rule
possibl
regul
autophagosom
confirm
independ
degrad
autophagosom
process
test
whether
rapamycinmedi
degrad
could
occur
autophagydefici
cell
ko
cell
accumul
turnov
prevent
degrad
appar
si
appendix
fig
togeth
result
suggest
mtor
inhibitor
result
deliveri
endolysosom
autophagosomeindepend
manner
contrast
knockdown
escrti
compon
partial
prevent
degrad
rapamycin
determin
flow
cytometri
fig
western
blot
fig
enhanc
immunoblot
reveal
coval
modif
approxim
nine
kilodalton
rapamycintr
cell
may
repres
singl
ubiquitin
moieti
fig
function
requir
escrt
machineri
rapamycininduc
degrad
suggest
mtor
inhibit
promot
ubiquitin
sort
mvb
dispos
lysosom
support
strong
associ
mvb
marker
cell
treat
rapamycin
bafilomycin
si
appendix
fig
probe
direct
involv
mtor
associ
complex
event
lead
degrad
perform
rna
interfer
silenc
compon
raptor
compon
rictor
rel
treatment
nontarget
control
sirna
thorough
silenc
raptor
effect
protein
level
contrast
slight
reduct
rictor
result
decreas
si
appendix
fig
e
specif
albeit
modest
effect
rictor
knockdown
suggest
inhibit
may
mean
rapamycin
lead
degrad
role
consist
previou
observ
indic
rapamycin
inhibit
activ
phosphoryl
akt
suppress
cell
prolifer
use
micromolar
concentr
rapamycin
treatment
hspc
result
downregul
given
rapamycin
initi
describ
enhanc
lentivir
transduct
hspc
explor
effect
mtor
inhibit
endogen
primari
cell
type
readili
detect
cell
deriv
pool
cord
blood
nine
donor
rapamycin
treatment
led
mark
decreas
level
determin
flow
cytometri
fig
also
assess
consequ
drug
treatment
cell
adult
peripher
blood
use
confoc
microscopi
analysi
fig
intriguingli
signal
elev
follow
addit
lentivector
suggest
viru
addit
mobil
endosom
primari
cell
type
result
assess
endosom
protein
necessit
addit
lentivector
shown
cord
blood
cell
rapamycin
treatment
adult
cell
led
dosedepend
downregul
redistribut
perinuclear
site
fig
ifitm
silenc
abrog
rapamycinmedi
enhanc
lentivector
transduct
preced
experi
collect
demonstr
mtor
inhibit
neg
regul
variou
cell
type
remain
test
whether
phenomenon
account
rapamycinmedi
enhanc
lentivir
transduct
report
previous
hspc
reproduc
condit
use
hspc
hela
cell
incub
micromolar
rapamycin
h
lentivector
exposur
product
transduct
score
de
novo
gag
express
found
rapamycin
treatment
hela
cell
increas
permiss
lentivector
bear
vsvg
threeto
fourfold
fig
partial
knockdown
use
shrna
result
transduct
rate
similar
follow
drug
treatment
fig
b
c
importantli
rapamycin
treatment
knockdown
cell
led
even
higher
transduct
rate
enhanc
effect
drug
rel
diminish
less
twofold
fig
result
suggest
function
rapamycin
transduct
enhanc
depend
level
endogen
fulli
suppress
protein
product
well
target
three
gene
product
mixtur
sirna
previous
describ
hela
cell
silenc
influenc
rapamycin
transduct
absent
fig
sinc
ifitm
protein
known
inhibit
infect
viruscel
fusion
use
fretbas
assay
measur
earli
step
viru
entri
cell
result
indic
rapamycin
enhanc
lentivector
transduct
hela
promot
viruscel
fusion
consist
find
hspc
fig
moreov
deplet
led
increas
viruscel
fusion
enhanc
observ
rapamycin
fig
therefor
rapamycin
enhanc
viruscel
fusion
larg
extent
downregul
ifitm
protein
express
western
blot
analysi
use
establish
effici
specif
rnai
reagent
downregul
ifitm
protein
experi
fig
f
g
si
appendix
fig
also
provid
evid
endogen
addit
neg
regul
rapamycin
fig
detect
like
ubiquitin
form
cell
treat
rapamycin
bafilomycin
form
absent
cell
si
appendix
fig
combin
rapamycin
rnai
primari
hff
confirm
rapamycinmedi
lentivir
transduct
enhanc
requir
ifitm
protein
fig
furthermor
achiev
robust
specif
gene
knockout
use
found
major
determin
rapamycin
sensit
hela
fig
tzmbl
cell
fig
si
appendix
fig
ce
function
broadli
inhibit
mani
pathogen
rna
virus
cell
cultur
experi
physiolog
impact
best
character
iav
infect
mice
human
consist
abil
coordin
select
clearanc
cell
found
rapamycin
also
promot
infect
iav
hela
hff
ifitmdepend
manner
fig
ac
rel
vsvgmediat
viru
entri
iav
infect
sensit
inhibit
rapamycin
treatment
led
greater
degre
infect
enhanc
silenc
knockout
experi
indic
express
requir
observ
enhanc
viral
infect
rapamycin
establish
whether
suffici
confer
rapamycin
sensit
cell
perform
experi
mous
embryon
fibroblast
mef
ifitmdefici
mice
iav
infect
cell
lack
murin
ifitm
protein
significantli
boost
rapamycin
treatment
fig
contrast
complement
cell
murin
result
inhibit
infect
restrict
partial
reliev
follow
rapamycin
treatment
fig
analysi
protein
level
complement
cell
reveal
murin
partial
downregul
rapamycin
level
partial
restor
presenc
bafilomycin
fig
result
suggest
express
alon
confer
sensit
rapamycinmedi
infect
enhanc
effect
solidifi
function
relationship
endogen
ifitm
protein
effect
mtor
inhibit
viru
infect
find
sendai
viru
paramyxoviru
resist
effect
rapamycin
treatment
ifitm
silenc
fig
neither
rapamycin
treatment
ifitm
knockdown
led
enhanc
sendai
viru
infect
therefor
rapamycin
enhanc
infect
ifitmsensit
virus
ifitmresist
virus
demonstr
primari
mechan
mtor
inhibit
promot
infect
downmodul
protein
result
outlin
describ
caus
consequ
select
protein
degrad
program
follow
mtor
inhibit
within
manner
minut
rapamycin
treatment
result
neg
regul
posttransl
level
divers
cell
type
find
reminisc
recent
report
describ
mtor
inhibitor
activ
extens
degrad
cellular
protein
via
proteasom
autophagi
pathway
possibl
belong
suit
protein
subject
regul
mtor
inhibit
show
certain
endosom
protein
transferrin
receptor
spare
process
importantli
experi
demonstr
protein
downregul
account
major
infect
enhanc
effect
observ
indic
degrad
follow
rapamycin
treatment
cell
basal
condit
follow
ectop
induc
express
unaffect
domin
sourc
restrict
cell
assess
rel
abund
ifitm
protein
may
vari
tissu
microenvironment
cue
present
therein
addit
enhanc
infect
mediat
vsvg
iav
ha
like
mtor
inhibit
promot
infect
number
virus
pathogen
human
particular
interest
impact
sensit
ifitmmedi
restrict
earli
stage
entri
late
stage
virion
infect
life
cycl
straindepend
manner
furthermor
drug
condit
lead
mtor
inhibit
expect
impact
cellular
process
involv
cellcel
adhes
cytokin
regul
inde
studi
effect
may
reveal
physiolog
basi
interconnected
mtor
ifitm
protein
local
ifitm
protein
endomembran
led
other
conclud
featur
process
macroautophagi
overexpress
result
elev
autophagosom
marker
recent
shown
shuttl
cellular
protein
autophagosom
degrad
latter
find
reveal
inhibit
ifn
signal
cell
migrat
respect
provid
exampl
ifitm
protein
influenc
immun
mani
way
nonetheless
result
suggest
substrat
regul
macroautophagi
least
context
explor
studi
instead
show
neg
regul
rapamycin
involv
endosom
traffick
event
like
guid
ubiquitin
escrtmedi
sort
mvb
earlier
report
discov
abund
finetun
ubiquitin
ligas
recogn
tyrosinebas
motif
ppxi
amino
terminu
shown
ubiquitin
acceler
turnov
human
murin
cell
known
ubiquitin
cargo
protein
sort
escrt
explicitli
rule
role
rapamycinmedi
degrad
partial
escap
effect
mtor
inhibit
display
mutant
lack
ppxi
motif
lack
lysin
residu
previous
shown
target
ubiquitin
howev
sinc
ubiquitin
ligas
includ
itch
also
recogn
ppxi
motif
protein
substrat
regul
turnov
may
control
multipl
ligas
result
use
deplet
link
ifitm
protein
escrt
machineri
remain
seen
whether
escrt
govern
rel
amount
local
basal
homeostasi
cellular
stress
mtor
inhibit
irrespect
ligas
respons
redirect
acid
endolysosom
function
requir
escrt
impli
mvb
repres
intermedi
pass
lysosom
deliveri
degrad
consist
role
mvb
degrad
interrupt
bafilomycin
accumul
multivesicular
saclik
structur
arriv
transient
compart
escrt
may
coordin
sort
late
endosom
andor
lysosom
membran
membran
invagin
known
ilv
fusion
mvb
termin
lysosom
perinuclear
site
bafilomycin
may
facilit
transfer
ilv
lysosom
lumen
degrad
hydrolas
note
ilv
also
releas
cell
mvb
fuse
plasma
membran
process
known
exocytosi
sinc
protein
regularli
detect
viru
particl
extracellular
vesicl
express
high
level
cell
possibl
mtor
inhibit
augment
pool
eject
extracellular
space
addit
lysosom
lumen
cell
exterior
cargo
within
ilv
also
gain
access
cytoplasm
undergo
backfus
limit
membran
mvb
fact
initi
believ
undergo
viruscel
fusion
earli
endosom
evid
exist
vsvg
use
backfus
step
mvb
complet
cytoplasm
entri
thu
togeth
wellcharacter
low
ph
trigger
requir
iav
hamedi
fusion
viral
glycoprotein
util
studi
display
depend
late
endosomalmvb
membran
previou
studi
employ
overexpress
document
endolysosom
express
pattern
cell
suggest
subcellular
local
underli
abil
restrict
virus
enter
site
howev
observ
endogen
local
mainli
earli
endosom
hela
cell
possibl
viru
restrict
occur
intern
viru
particl
overlap
traffick
endosom
matur
toward
late
phenotyp
furthermor
viru
infect
driven
vsvg
less
sensit
restrict
rel
iav
ha
may
reflect
differenti
depend
late
endosomalmvb
membran
entri
qualit
differ
interact
said
membran
insensit
sendai
viru
ifitm
protein
rapamycin
treatment
like
attribut
abil
fuse
plasma
membran
worthwhil
assess
viru
infect
ifn
signal
impact
abund
differ
endosom
compart
data
present
herein
provid
mechanist
understand
rapamycin
facilit
lentivir
transduct
cell
ex
vivo
also
rais
import
question
regard
use
vivo
pharmacolog
mtor
inhibit
current
use
inhibit
metabol
disord
neurodegener
age
graft
reject
tumorigenesi
certain
applic
alreadi
receiv
food
drug
administr
fda
approv
howev
limit
level
endosom
exposur
rapamycin
may
undermin
import
compon
cellintrins
antivir
immun
inde
human
immunocompromis
mtor
inhibitor
cancer
treatment
follow
organ
transplant
exhibit
increas
incid
respiratori
tract
infect
includ
caus
virus
iav
furthermor
administr
rapamycin
vivo
shortli
infect
iav
led
exacerb
diseas
mortal
mice
human
natur
occur
singl
nucleotid
polymorph
result
decreas
mrna
express
associ
sever
outcom
follow
iav
infect
reduc
express
physiolog
impact
highlight
need
investig
molecular
player
link
mtor
pathway
work
suggest
complex
respons
regul
sinc
silenc
rictor
alon
led
detect
decreas
protein
howev
transient
natur
downregul
follow
mtor
inhibit
exist
feedback
loop
impli
genet
approach
identifi
gene
respons
challeng
would
benefici
determin
whether
calor
restrict
like
exposur
rapamycin
influenc
express
modul
vulner
viru
infect
enhanc
gene
transduct
rate
hspc
highli
valu
field
gene
therapi
even
increment
improv
rais
probabl
achiev
therapeut
benefit
patient
howev
use
mtor
inhibitor
carri
risk
mtordepend
process
may
interrupt
cell
prolifer
surviv
method
enabl
specif
target
abund
function
ex
vivo
like
provid
greater
degre
transduct
enhanc
without
impair
reconstitut
potenti
vivo
cell
human
donor
cord
blood
cb
gener
donat
cleveland
cord
blood
center
cleveland
isol
cell
adult
mobil
peripher
blood
cell
obtain
fred
hutchinson
cancer
research
center
process
procur
core
approv
institut
protocol
scripp
research
institut
virus
infect
replicationincompet
lentivector
hivvsvg
produc
transfect
gift
schwartz
institut
pasteur
pari
vsvg
addgen
use
calcium
phosphat
method
briefli
six
million
cell
seed
flask
plasmid
dna
mix
steril
h
cacl
trisedta
te
buffer
total
combin
hepesbuff
salin
hb
transfect
volum
ad
dropwis
cell
incub
h
supernat
clarifi
centrifug
pass
filter
store
lentivector
titer
measur
use
elisa
kit
xpressbio
produc
lentivector
fretbas
viruscel
fusion
measur
transfect
vsvg
addgen
hela
cell
seed
plate
per
well
overnight
overlaid
ng
equival
blamvprcontain
hivvsvg
h
cell
wash
label
load
kit
invitrogen
addit
h
analyz
viruscel
fusion
describ
influenza
viru
sendai
viru
cantel
strain
suppli
clarifi
allanto
fluid
purchas
charl
river
laboratori
infecti
viru
titer
calcul
use
flow
cytometrybas
method
hela
cell
infect
perform
follow
cell
seed
plate
per
well
overnight
overlaid
indic
amount
viru
final
volum
h
cell
wash
pb
detach
trypsinedta
fixedpermeabil
cytofixcytoperm
immunostain
antibodi
iav
np
sev
protein
respect
analyz
flow
cytometri
flow
cytometri
cell
fixedpermeabil
cytofixcytoperm
reagent
bd
min
wash
permwash
buffer
bd
cell
pellet
resuspend
primari
antibodi
dilut
permwash
buffer
incub
room
temperatur
min
wash
permwash
buffer
cell
pellet
resuspend
alexa
fluorconjug
secondari
antibodi
dilut
permwash
buffer
incub
room
temperatur
min
wash
permwash
buffer
cell
acquir
analyz
lsrfortessa
bd
follow
primari
antibodi
use
score
viru
infect
antihiv
gag
bd
gag
nih
aid
reagent
resourc
antiiavnp
abcam
antisev
mbl
endogen
measur
abcam
exogen
wt
mutant
express
pqcxip
measur
antiflag
sigma
endogen
measur
santa
cruz
biotechnolog
clone
bd
follow
reagent
obtain
bei
resourc
niaid
nih
human
recombin
ifn
beta
plasmid
transfect
rna
interfer
knockout
carboxyltermin
tag
gift
v
pathak
nation
cancer
institut
frederick
md
transfect
tzmbl
hela
cell
use
miru
aminotermin
tag
genecopoeia
transfect
hela
cell
use
miru
stabli
express
cell
creat
follow
select
wk
gift
c
liang
mcgill
univers
montreal
mutant
contain
aminotermin
flag
previous
describ
transfect
cell
miru
stabli
express
cell
creat
follow
select
puromycin
wk
hela
cell
stabli
express
shrna
creat
transduct
pgipzgfpbas
lentivector
express
shrna
scrambl
control
thermo
fisher
hela
tzmbl
ko
cell
creat
transfect
set
plasmid
encod
three
guid
rna
santa
cruz
biotechnolog
set
three
plasmid
provid
templat
homologydirect
repair
santa
cruz
biotechnolog
popul
modifi
cell
select
follow
puromycin
treatment
wk
hela
sdspage
western
blot
analysi
whole
cell
lysi
perform
radioimmunoprecipit
assay
ripa
buffer
thermo
fisher
supplement
halt
proteas
inhibitor
mixtur
edtafre
thermo
fisher
lysat
clarifi
centrifug
supernat
collect
store
protein
concentr
determin
protein
assay
kit
ii
biorad
protein
load
acrylamid
criterion
xt
bistri
precast
gel
biorad
electrophoresi
run
nupag
me
sd
run
buffer
invitrogen
protein
transfer
amersham
protrain
premium
nitrocellulos
membran
pore
size
ge
healthcar
membran
block
odyssey
block
buffer
pb
licor
incub
dilut
follow
primari
antibodi
proteintech
proteintech
abcam
proteintech
antitransferrin
receptor
abcam
mbl
proteintech
abcam
antiraptor
thermo
fisher
antirictor
cell
signal
technolog
antiactin
santa
cruz
biotechnolog
antitubulin
santa
cruz
biotechnolog
secondari
antibodi
conjug
dylight
licor
licor
odyssey
imag
system
use
reveal
specif
protein
detect
imag
analyz
assembl
use
imagestudiolit
licor
